Options-implied volatility suggests Abbott Laboratories shares could move about 4.5% when the company posts its quarterly earnings on July 16 ahead of the market open, based on options data compiled by Bloomberg.
That implied magnitude has not always captured the full extent of Abbott's post-earnings reactions. In fact, the stock has moved beyond the options-implied level in five of the last eight earnings disclosures.
Notable recent instances include an April session when shares fell 7.8% despite an implied move of 3.2%. Earlier in the year, in January, the stock declined 13.1% against an implied move of 3.6%.
Additional historical comparisons cited over a broader timeframe show mixed alignment with implied expectations. In October 2025, the stock fell 2.7% while the implied move was 3.4%. On July 17, 2025, shares dropped 9.5% versus an implied move of 2.8%. In April 2025, the stock rose 4.6% compared with an implied move of 4.2%.
Further past outcomes include a 4.2% gain on January 22, 2025, where the implied move had been 3.1%. On October 16, 2024, shares rose 2.8% against an implied move of 3.9%. And on July 18, 2024, the stock fell 2.9% compared with an implied move of 3.9%.
Those historical data points illustrate that while options markets provide a baseline expectation for how much the stock might shift, actual market reactions around Abbott's quarterly reports have at times been markedly larger or smaller than the implied numbers.
Key points
- Options pricing implies a 4.5% move for Abbott Laboratories shares on the July 16 earnings release, before the market opens.
- Abbott has exceeded the implied move in five of its last eight earnings reports, indicating episodic, larger-than-expected volatility.
- Sectors impacted include healthcare-equity markets and broader stock market ETFs that include medical device and diagnostics names.
Risks and uncertainties
- Actual share price movement may diverge materially from the options-implied 4.5% figure, as shown by past earnings where moves were both larger and smaller than implied - relevant to investors in healthcare and broader equity markets.
- Historical volatility around quarterly reports suggests event-driven price risk for traders and portfolio managers with exposure to Abbott and related medical device and diagnostics stocks.
This article reports the options-implied expectation for Abbott's upcoming earnings and lists past post-earnings price outcomes. It does not attempt to explain causes for any specific move, nor does it introduce forecasts beyond the options-derived implied move and the documented historical results above.